Clinical Trials and Research Studies
Phase 1/2
A Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Learn MorePhase 1
A PHASE I AND EXPANSION COHORT STUDY OF ADJUVANT CISPLATIN INTENSITY-MODULATED RADIOTHERAPY AND MK-3475 (PEMBROLIZUMAB) IN HIGH-RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Learn MorePhase 1
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
Learn MorePhase 1
A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad
Learn More